BEIJING, Oct. 9, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with comprehensive structural heart disease ...
Favorable mortality and heart failure hospitalization rates, along with improved functional status, observed among recipients of LuX-Valve device for severe symptomatic tricuspid regurgitation. Single ...
WASHINGTON, Nov. 1, 2024/PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for ...
BEIJING, June 2, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of ...
The race to develop transcatheter systems for tricuspid regurgitation (TR) continues, and early-stage report cards are in for several investigational devices. Progress with transcatheter tricuspid ...
TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results